FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
- Written by PR Newswire Asia - Asian Spectator
HIGHLIGHTS
- The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in the USA
- The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in the USA
MELBOURNE, Australia, Jan. 18, 2024 /PRNewswire/ -- Amplia Therapeutics...



